Proviron – Mesterolone 25mg
Proviron is presented in the ORYVION catalog as a tablet formulation containing 25mg of mesterolone per tablet, supplied in containers of 30 tablets. Mesterolone is an orally active androgen with a reported terminal elimination half-life of approximately 12–13 hours.
Its pharmacological profile includes androgenic activity, with medical applications in conditions associated with androgen deficiency. Mesterolone binds extensively to circulating proteins, including sex hormone-binding globulin (SHBG) and albumin. It is not metabolically converted into estrogens; this characteristic does not establish that it lowers estrogen levels or prevents estrogen-related adverse effects from other compounds.
Product Specifications:
Commercial name: Proviron
Listed compound: Mesterolone
Declared strength: 25mg per tablet
Format: Tablets
Package contents: 50 tablets
Important Note:
Mesterolone can cause acne, hair loss, and prolonged or painful erections. It is contraindicated in people with prostate cancer or previous or existing liver tumors. Misuse, particularly alongside other anabolic-androgenic steroids, carries serious cardiovascular, hepatic, psychiatric, and dependence risks.
All products sold by ORYVION are intended for laboratory research purposes only and are not approved for human consumption, medical use, or veterinary applications. These compounds are not classified as dietary supplements or pharmaceuticals.
ORYVION operates strictly within the legal frameworks of the jurisdictions in which it conducts business. Sales are limited to countries and regions where the possession and use of research chemicals are permitted by law. It is the sole responsibility of the purchaser to ensure compliance with local, national, and international laws and regulations.
By purchasing, the customer affirms that they are at least 21 years of age, legally authorized to receive such materials, and fully aware of their intended use. ORYVION disclaims all liability for misuse, improper handling, or any consequences resulting from non-compliant use of these products.
ORYVION complies with relevant provisions under EU’s Pharmaceutical and Medical Device Act, as well as applicable international guidelines regarding non-pharmaceutical research compounds.